Global Clinical Oncology Next Generation Sequencing Market by Application (Companion Diagnostics, Screening), by Technology (WES, WGS) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global clinical oncology next-generation sequencing market was valued at USD 299.9 million in 2020. It is expected to grow at a compound annual rate (CAGR), of 14.70% between 2021 and 2028. This technology allows for the efficient and cost-effective sequencing tumor DNA. This has led to a new era in cancer research and treatment. Next-generation sequencing (NGS), has made significant advances in personalized medicine for cancer. Because the technology allows for the identification of resistance mechanisms, germline and somatic mutations and quantification of the mutational burden of cancers, this is a significant advance in personalized medicine for oncology. These factors will aid in increasing NGS' clinical utility in precision oncology care.

The clinical use of next-generation sequencing in precision cancerology has driven companies to create new platforms that can be used in genomic assays. Congenica partnered with Gabriel Precision Oncology Ltd. in February 2021 to create an automated clinical oncology interpretation platform.

This product will allow routine clinical practice to use NGS-based molecular diagnosis of tumors. 4baseCare, a precision-oncology startup, partnered with Advanced Centre for Treatment, Research and Education in Cancer, India (ACTREC) to create ClinOme, an AI-driven clinical interpretation platform.

This platform analyzes NGS raw data. It is used by clinicians for the categorizing and interpretation of genomic alterations, as well as experimental and approved therapies to each genotype-drug combination. This increases the number of NGS data analysis platforms that can be used for personalized oncology treatment.

Technology Insights

With a market share of more than 72%, the targeted sequencing and resequencing segment was dominant in 2020. Targeted cancer sequencing panels reduce time and cost of sequencing tumor samples. The clinical utility of targeted panels for diagnosing malignant tumors is increased by their efficiency. A 2020 study in JCO Precision Oncology found that NGS panels can be clinically helpful in 64% of cases of cancer.

Segment growth is also driven by the adoption and development of targeted panels that target tumor-associated microorganisms as well as oncology?related gene. Illumina's 523-gene panel includes all genes that could lead to the development of malignant tumours. Clinical laboratories use the product to diagnose acute myeloidleukemia patients.

Whole-Genome Sequencing is expected to grow rapidly from 2021-2028 due to its ability to distinguish normal tissue from tumor tissues. Whole-genome sequencing is a way to identify and target mutations ahead of time. This allows for the development of a treatment plan based on the affected genes and helps to analyze the prognosis.

Workflow insights

Sequencing was the most revenue-generating workflow segment for 2020, accounting for over 54% of total revenue. Sequencing is an essential step in the workflow. It requires advanced platforms. Segment growth is also boosted by an increase in cancer sequencing projects. The Pan-Cancer Analysis of Whole Genomes Consortium (PCAWG Consortium) analyzed 38 types of cancer by sequencing more than 2,600 samples.

The pre-sequencing market is thriving because of the efforts made by key players to lower the cost for NGS library preparation. In January 2021, for instance, Thermo Fisher Scientific and SPT Labtech signed a comarketing agreement to lower the cost of NGS library preparation. This was in order to detect variants of cancer and infectious diseases.

NGS data analysis is expected to expand at a rapid pace. The segment's growth is driven by the efforts of key market players to develop sophisticated computational tools. CopyKAT was developed by scientists at the MD Anderson Cancer Center in January 2021 to help distinguish between cancerous and normal cells within a tumor.

Application Insights

Screening was the most lucrative revenue stream with 79%. NGS is widely used in cancer screening programs around the world. NGS-based testing currently is the most effective method to identify genetic alterations that could be targeted for clinical benefit in patients with cancer. This technology allows clinicians simultaneously to assess multiple gene alterations.

The technology also requires less tumor tissue than other pathology methods. From 2021 to 2028, the fastest projected CAGR will be in the companion diagnostics segment. NGS adoption for companion diagnostics will be boosted by product development and partnerships between key players.

Resolution Bioscience, Inc., for instance, entered into an agreement with LabCorp in February 2020 to make its Resolution ctDx lung assay more accessible to patients and clinicians. The diagnostic test is fast and non-invasive, and it detects actionable mutations in Non-Small Cell Lung Cancer. The company's cell-free DNA platform powers the assay, which includes NGS biochemistry (and cloud-based bioinformatics).

End-use Insights

With a market share of more than 65%, the laboratories segment led in 2020. Complex workflows can be time-consuming for laboratories. Most advanced laboratories use pre-existing workflows based on standard procedures.

NGS testing has been revolutionized by the rapid development and availability of NGS assays. Therefore, guidelines have been created for NGS testing. To demonstrate the validity and reliability of the results, FDA-approved tests include established standards, controls, and performance characteristics.

The U.S. has several regulatory bodies that regulate clinical laboratories. Through Clinical Laboratory Improvement Amendments, (CLIA), the CMSs regulate laboratory testing. These are also governed by state-level entities that may have more stringent regulations than CLIA. Other organizations such as the Association of Molecular Pathology, American College of Medical Genetics and Genomics, and College of American Pathologists have also established the best guidelines for clinical labs.

Regional Insights

With a market share of over 49%, North America was the dominant country in the global clinical oncology NGS industry. This growth is due to the significant efforts of regulatory bodies to improve cancer screening diagnosis in America. The Cancer Genome Atlas program, initiated by the U.S. National Cancer Institute, (NCI), has done next-generation sequencing on more than 20,000 primary samples from 33 types of cancer.

The NCI's Cancer Target Discovery and Development Network includes 12 cancer centers across the U.S., including Johns Hopkins University and Dana-Farber Cancer Institute. The growth of the regional market is also attributed to the existence of many laboratories, universities, and hospitals offering NGS-based services for early detection and treatment of cancer.

EasyDNA Canada, a Toronto-based DNA testing firm, offers tests called Cancer Predisposition Panel that use NGS technology. It detects mutations in 98 genes linked to 25 hereditary types of cancer. This test can help identify individuals who are at high risk for developing cancer in later stages of their lives.

Market Share Insights & Key Companies

There are many small and medium-sized companies that have made significant efforts to increase their market presence. In May 2020, Burning Rock Biotech Limited, a China-based provider of cancer testing, partnered up with Illumina to help promote standardization and the development NGS-based treatment selection in China. Myriad Genetics, Inc. also signed an agreement for myChoice tumor testing to be developed and commercialized in China. These are some of the major companies that make up the global clinical oncology next-generation sequencing market:

• Illumina, Inc.

• Thermo Fisher Scientific

• F. Hoffmann-La Roche Ltd.

• Agilent Technologies

• Myriad Genetics

• Beijing Genomics Institute (BGI)

• Perkin Elmer

• Foundation Medicine

• Pacific Bioscience

• Oxford Nanopore Technologies Ltd.

• Paradigm Diagnostics

• Caris Life Sciences

• Partek, Inc.

• Eurofins Scientific S.E.

• Qiagen N.V.

Up Market Research published a new report titled “Clinical Oncology Next Generation Sequencing Market research report which is segmented by Application (Companion Diagnostics, Screening), by Technology (WES, WGS), By Players/Companies Inc; Caris Life Sciences; and Eurofins Scientific, Inc; Qiagen NV; Partek, Inc; Pacific Bioscience, Roche, Inc; Foundation Medicine; Oxford Nanopore Technologies Ltd; Paradigm Diagnostics, Agilent; Thermo Fisher Scientific; Myriad Genetics; Beijing Genomics Institute (BGI); Perkin Elmer, Illumina”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Clinical Oncology Next Generation Sequencing Market Report Segments:

The market is segmented by Application (Companion Diagnostics, Screening), by Technology (WES, WGS).

Clinical Oncology Next Generation Sequencing Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Clinical Oncology Next Generation Sequencing Market

Overview of the regional outlook of the Clinical Oncology Next Generation Sequencing Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Clinical Oncology Next Generation Sequencing Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Clinical Oncology Next Generation Sequencing Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Companion Diagnostics

                2. Screening

                1. WES

                2. WGS

8. Market scenario by region, sub-region, and country.
9. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
10. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
11. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Clinical Oncology Next Generation Sequencing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Clinical Oncology Next Generation Sequencing Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.